Table 3.
Univariate and multivariate analysis of bPFS in all patients.
| Characteristic | n (%) | Univariable |
Multivariable |
||
|---|---|---|---|---|---|
| HR（95%CI） | p | HR（95%CI） | p | ||
| Sex（Female VS. Male) | 24 (25.3) | 1.31 (0.71–2.43) | .392 | ||
| Age (>65 VS. ≤65) | 31 (32.6) | 1.02 (0.57–1.84) | .947 | ||
| Smoking, Yes, n (%) | 45 (47.4) | 1.24 (0.72–2.14) | .444 | ||
| ECOG PS (≥2 VS.0–1) | 11 (11.6) | 2.70 (1.16–6.30) | .021 | 2.07 (0.86–4.96) | .103 |
| Clinical stage (IVb VS. IVa) | 83 (87.4) | 1.20 (0.51–2.81) | .679 | ||
| Pathology | |||||
| Adenocarcinoma | 73 (76.8) | - | |||
| Squamous | 15 (15.8) | 1.89 (0.98–3.64) | .059 | 1.59 (0.81–3.15) | .179 |
| Other | 7 (7.4) | 0.89 (0.27–2.90) | .847 | 1.91 (0.54–6.74) | .311 |
| EGFR, Yes, n (%) | 16 (16.8) | 1.64 (0.79–3.41) | .185 | ||
| KRAS, Yes, n (%) | 11 (11.6) | 0.42 (0.15–1.17) | .098 | ||
| PD-L1 expression | |||||
| <1% | 18 (18.9) | - | |||
| 1–49% | 13 (13.7) | 1.14 (0.44–2.98) | .783 | ||
| ≥50% | 17 (17.9) | 0.60 (0.22–1.63) | .316 | ||
| NA | 47 (49.5) | 1.10 (0.55–2.21) | .795 | ||
| anti-angiogenic agents, Yes, n (%) | 42 (44.2) | 0.49 (0.28–0.86) | .013 | 0.55 (0.30–0.99) | .047 |
| Line (≥2 VS.1) | 41 (43.2) | 1.11 (0.63–1.94) | .719 | ||
| Bone targeting agents, Yes, n (%) | 55 (57.9) | 0.86 (0.49–1.49) | .583 | 0.64 (0.34–1.20) | .165 |
| Number (≥2 VS.1) | 70 (73.7) | 0.99 (0.54–1.84) | .984 | ||
| SRE, Yes, n (%) | 31 (32.6) | 2.93 (1.67–5.17) | <.001 | 2.93 (1.50–5.70) | .002 |
| Other metastases, Yes, n (%) | 71 (74.7) | 1.22 (0.65–2.28) | .544 | ||
| Brain, Yes, n (%) | 24 (25.3) | 1.45 (0.80–2.65) | .223 | ||
| Liver, Yes, n (%) | 21 (22.1) | 1.41 (0.75–2.66) | .286 | ||
| Adrenal glands, Yes, n (%) | 10 (10.5) | 0.60 (0.22–1.68) | .331 | ||
| Pleura, Yes, n (%) | 52 (54.7) | 2.05 (1.16–3.63) | .014 | 1.54 (0.83–2.86) | .174 |
bPFS, progression-free survival of bone metastases lesions; ECOG PS, Eastern Cooperation Oncology Group performance status; EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; PD-L1, programmed cell death-ligand 1; SRE, skeletal-related event.